Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis Does Not Affect Rates of Infection, Malignancy and Autoimmune Events: Results From Pooled Clinical Trial Data. Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) Genovese, M. C., Hochberg, M. C., Cohen, R. B., Weinblatt, M. E., Kaine, J., Keystone, E., Nash, P., Delaet, I., Alten, R. WILEY-BLACKWELL. 2012: S725–S725
View details for Web of Science ID 000309748303416